Key Points
People who stopped taking Eli Lilly & Co.s Zepbound after about eight months regained half the weight theyd lost a year later, yet were significantly thinner than when they had started the obesity drug, according to a study..
Taking Zepbound for 36 weeks resulted in a 20.9% loss of body weight, according to the study published Monday in the Journal of the American Medical Association..
But after 88 weeks, a group no longer taking the drug after the first 8 months had still lost 9.9% of their weight..
Earlier studies have shown that people who stop taking popular obesity drugs from Lilly and Novo Nordisk A/S called GLP-1s are prone to regaining weight..
Still, the results indicate that some benefits are retained a full year later, said Louis Aronne, an obesity expert at Weill Cornell Medicine and lead study author..
You might be interested in
Drug used to treat diabetes could help obese people lose weight: Study
27, Oct, 23The diabetes drug Mounjaro has helped people with obesity to lose at least a quarter of their body weight, or about 60 pounds on average when combined with intensive diet and exercise, as per a new study.
Weight loss drugs transforming healthcare, may help with addiction
09, Nov, 23A new class of weight loss drugs is transforming the U.S. healthcare system in ways that could extend to equally hard-to-treat areas like substance abuse, according to speakers at the Reuters Events Total Health conference in Chicago this week.
Almost half of children on the weight-loss drug semaglutide are no longer clinically obese, landmark study finds
18, May, 23A study by Minnesota University found that 45% of children who took the jab once a week for more than a year dropped enough weight to be out of the medically-concerning range.
Lilly experimental 'triple G' obesity drug leads to 24.2% weight loss in trial
27, Jun, 23Eli Lilly on Monday said a mid-stage trial of its next-generation obesity drug candidate "triple G" showed that it led to weight loss of up to 24.2% after 48 weeks, surpassing results seen with other weight loss drugs.
Eli Lilly's Zepbound: Here's what to know about new obesity drug approved by FDA
09, Nov, 23The US Food and Drug Administration has approved a new obesity drug- Zepbound
Avoid weight gain after Ozempic with 'maintenance dose': Doctor
25, Mar, 23Weight gain is a common experience among people who stop taking Ozempic. One doctor is experimenting with tapering off slowly to keep weight low.
Lilly weight-loss drug Zepbound gets US, UK approval to rival Wegovy
09, Nov, 23U.S. and UK regulators both gave thumbs up to Eli Lilly's weight-loss treatment. The drugs are the most effective treatments for weight loss approved to date. | Health
Tirzepatide, another diabetes drug cleared for weight loss in US, yet to get regulator nod in India
20, Nov, 23In clinical trials, tirzepatide by Eli Lilly has shown to reduce body weight by up to 22.5 percent, on average, after about 72 weeks, according to the company.
Why People Stop Using Drugs Like Ozempic
07, Jul, 23Drugs like semaglutide—better known as Ozempic or Wegovy—could be lifelong treatments for obesity, but what little data scientists have suggests that people don't stick with them for long.
Roche enters obesity drugs race with $2.7 bln Carmot deal
04, Dec, 23The race to grab a slice of the lucrative market for obesity treatments is heating up among drugmakers, with Swiss company Roche (ROG.S) becoming one of the latest entrants following its $2.7 billion deal to buy Carmot Therapeutics (CRMO.O).